Mergers & Acquisitions ·
XTL Biopharmaceuticals acquires Psyga Bio for up to 58.36% of capital plus $1.5M private placement
XTLBXtl Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd. consummated its acquisition of Psyga Bio Ltd. on June 30, 2026, acquiring approximately 83.40% of Psyga Bio's share capital through the issuance of ADSs representing up to 33.36% of XTL's issued and outstanding capital. The transaction includes milestone-based additional ADS or warrant issuance representing up to 25% of the Company's capital. Concurrently, the company completed a following private placement of US$1,500,000 at US$2.70 per ADS, which included warrants with adjustable exercise prices. XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on expanding its asset portfolio with IP-based assets.